By conducting a comprehensive analysis of genomic expression data, mutation profiles, and histological evaluations in a cohort comprising 111 HCC patients, researchers successfully developed an 11-gene signature which is able to predict response and survival outcomes in patients undergoing first-line anti-PD-1 therapy (Haber et al., 2023). Here, PDCD1 is linked to hepatocellular carcinoma.